Using AI to Make Cell Therapy More Accessible | CBS News Bay Area
November 5, 2026
CBS News Bay Area featured our CEO, Dr. Nina Horowitz, alongside cell therapy patient and advocate Laurie Adami in a segment on how artificial intelligence could make cell therapy available to far more patients.
The potential of cell therapy
Laurie was diagnosed with stage 4 follicular non-Hodgkin lymphoma in 2006 and spent more than a decade in treatment – including six different therapies – without remission. A single CAR T cell infusion completely cured her. Eight years later, she is still cancer-free. This is the incredible potential of cell therapy in action, and it’s what inspired the ImmuneBridge mission.
Unfortunately, cell therapies like Laurie’s are made of living cells, so they are complicated to manufacture, expensive, and highly variable. That keeps them out of reach for most patients. Our goal is to fix this by transforming the way developers design and manufacture these treatments.
Our approach: AI to find the best products, and novel manufacturing to scale them
ImmuneBridge uses AI and machine learning to screen candidate donors, cell types, processes, and modifications and then identify the top candidates for specific patient populations. This combinatorial space is massive and the multimodal data we are producing across hundreds of potential products would be impossible for humans to process. With AI, we can identify a candidate therapeutic for a wide variety of disease markets efficiently and affordably. Our proprietary manufacturing methods then increase the number of stem cells more than 1,000-fold in the umbilical cord blood units selected by our models as most optimal; this is enough to produce thousands of doses of high quality and affordable cell therapies from each unit.
“We are trying to optimize and standardize the manufacturing of cell therapy to bring the price down and to make it accessible for patients who otherwise would not be able to have these lifesaving treatments.” – Nina Horowitz, PhD
Read the full story from CBS News Bay Area here.
To collaborate, reach out to hello@immunebridge.com